Risk factors for arterial thrombosis in antiphospholipid syndrome

Neurological antiphospholipid syndrome: Clinical, neuroimaging, and pathological characteristics

“…The incidence of headache and that of cerebral infarction were ranked in the first and second respectively in this study, which was different with foreign literature. A comparison of the incidence of clinical manifestations between our study and that reported in foreign literature is presented in Table 3 [6][7][8][9][10].…”

“…According to an observational study of 1000 APS patients in 13 European countries, thrombotic events appeared in 166 (16.6%) patients during the first 5-year study period and in 115 (14.4%) during the second 5-year period [6]. APS patients with aCL who suffer from hypertension and hypertriglyceridaemia are at increased risk of arterial thrombosis [7].…”

Recurrent Pregnancy Loss and Cardiovascular Disease Mortality in Japanese Women: A Population-Based, Prospective Cohort Study

“…Patients with antiphospholipid syndrome have anticardiolipin antibodies [4]. These antibodies bind to phospholipids or phospholipid-binding proteins of platelet/endothelial cell membranes, enhance blood coagulation, and increase the risk of venous and arterial embolism [5,6]. A total of 18% of Italians with transient ischemic attack or ischemic stroke, aged 15-44 years, are positive for antiphospholipids [6].…”

“…Congenital haematological or vascular wall disorders may contribute to the risk of ischemic CVD mortality in younger adults [4][5][6][7]. A Danish population-based cohort study showed that the risks of ischemic stroke and myocardial infarction associated with each additional miscarriage were larger in women aged <35 years than those in older women [8].…”

Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study

“…A remarkable finding from our study was the association with arterial thrombosis. Even if deep vein thrombosis represents the most common feature of APS, arterial events constitute the most dangerous and potentially life-threatening manifestations of the disease, affecting primarily the central nervous system and young adults <50 years old (3,23,24) Although some progresses have been made in order to identify those patients who are at higher risk for developing arterial events, it still represents an urgent unmet clinical need (25)(26)(27).…”